Perspectives in GLP-1 research: new targets, new receptors
The incretin hormone glucagon-like peptide-1 (GLP-1) binds to and activates its G-protein-
coupled-receptor GLP-1R to reduce glycaemia through the stimulation of insulin and …
coupled-receptor GLP-1R to reduce glycaemia through the stimulation of insulin and …
Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes
B Cariou - Diabetes & metabolism, 2012 - Elsevier
The management of type 2 diabetes continues to evolve as new data emerge. Although
glycaemic control is still important, other risk factors–such as hypertension, dyslipidaemia …
glycaemic control is still important, other risk factors–such as hypertension, dyslipidaemia …
Cardiovascular effects of glucagon-like peptide-1 receptor agonists
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1
receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in …
receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in …
Glucagon-like peptide 1 in health and disease
In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …
The complexity of signalling mediated by the glucagon-like peptide-1 receptor
The glucagon-like peptide-1 receptor (GLP-1R) is a class B GPCR that is a major
therapeutic target for the treatment of type 2 diabetes. The receptor is activated by the …
therapeutic target for the treatment of type 2 diabetes. The receptor is activated by the …
Minireview: signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery
C Koole, EE Savage, A Christopoulos… - Molecular …, 2013 - academic.oup.com
The glucagon-like peptide-1 receptor (GLP-1R) controls the physiological responses to the
incretin hormone glucagon-like peptide-1 and is a major therapeutic target for the treatment …
incretin hormone glucagon-like peptide-1 and is a major therapeutic target for the treatment …
GLP-1R signaling and functional molecules in incretin therapy
W Wan, Q Qin, L Xie, H Zhang, F Wu, RC Stevens… - Molecules, 2023 - mdpi.com
Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes
mellitus (T2DM). The GLP-1R cellular signaling mechanism relevant to insulin secretion and …
mellitus (T2DM). The GLP-1R cellular signaling mechanism relevant to insulin secretion and …
[HTML][HTML] Incretin-based therapies: can we achieve glycemic control and cardioprotection?
FS Angeli, RP Shannon - Journal of Endocrinology, 2014 - joe.bioscientifica.com
Abstract Glucagon-like (GLP-1) is a peptide hormone secreted from the small intestine in
response to nutrient ingestion. GLP-1 stimulates insulin secretion in a glucose-dependent …
response to nutrient ingestion. GLP-1 stimulates insulin secretion in a glucose-dependent …
Glucagon-like peptide-1: glucose homeostasis and beyond
YM Cho, Y Fujita, TJ Kieffer - Annual review of physiology, 2014 - annualreviews.org
Glucagon-like peptide-1 (GLP-1), an incretin hormone secreted primarily from the intestinal
L-cells in response to meals, modulates nutrient homeostasis via actions exerted in multiple …
L-cells in response to meals, modulates nutrient homeostasis via actions exerted in multiple …
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
SA Brunton, CH Wysham - Postgraduate medicine, 2020 - Taylor & Francis
ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …